A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors

Hallmarks of Cancer: The Next Generation

Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590 · see citing works

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

Robert, C., Thomas, L., Bondarenko, I., O'Day, S., Weber, J., Garbe, C., Lebbe, C., Baurain, J.-F., Testori, A., Grob, J.-J., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1104621 · Cited by 4,496 · see citing works

Prevention of Allogeneic Fetal Rejection by Tryptophan Catabolism

Munn, D. H., Zhou, M., Attwood, J. T., Bondarev, I. E., Conway, S. J., Marshall, B., Brown, C. C., & Mellor, A. L. (1998) · Science · doi:10.1126/science.281.5380.1191 · Cited by 2,589 · see citing works

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

Uyttenhove, C., Pilotte, L., Théate, I., Stroobant, V., Colau, D., Parmentier, N., Boon, T., & Van den Eynde, B. J. (2003) · Nature Medicine · doi:10.1038/nm934 · Cited by 2,305 · see citing works

Inhibition of  T Cell Proliferation by Macrophage Tryptophan Catabolism

Munn, D., Shafizadeh, E., Attwood, J., Bondarev, I., Pashine, A., & Mellor, A. (1999) · Journal of Experimental Medicine · doi:10.1084/jem.189.9.1363 · Cited by 1,721 · see citing works

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy

Muller, A. J., DuHadaway, J. B., Donover, P. S., Sutanto-Ward, E., & Prendergast, G. C. (2005) · Nature Medicine · doi:10.1038/nm1196 · Cited by 1,064 · see citing works

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

Swain, S. M., Kim, S.-B., Cortés, J., Ro, J., Semiglazov, V., Campone, M., Ciruelos, E., Ferrero, J.-M., Schneeweiss, A., Knott, A., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(13)70130-x · Cited by 1,006 · see citing works

Tolerance, DCs and tryptophan: much ado about IDO

Grohmann, U. (2003) · Trends in Immunology · doi:10.1016/s1471-4906(03)00072-3 · Cited by 766 · see citing works

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4

Holmgaard, R., Zamarin, D., Munn, D. H., Wolchok, J. D., & Allison, J. P. (2013) · The Journal of Experimental Medicine · doi:10.1084/jem.20130066 · Cited by 633 · see citing works

The anticancer immune response: indispensable for therapeutic success?

Zitvogel, L., Apétoh, L., Ghiringhelli, F., André, F., Tesnière, A., & Kroemer, G. (2008) · Journal of Clinical Investigation · doi:10.1172/jci35180 · Cited by 572 · see citing works

Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer—Response

Sznol, M., & Chen, L. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2234 · Cited by 529 · see citing works

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

Bruno, R., Hille, D. A., Riva, A., Vivier, N., Huinink, W. W. T. B., van Oosterom, A. T., Kaye, S. B., Verweij, J., Fossella, F. V., Valero, V., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.1.187 · Cited by 424 · see citing works

IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan

Metz, R. A., Rust, S., DuHadaway, J. B., Mautino, M. R., Munn, D. H., Vahanian, N. N., Link, C. J., & Prendergast, G. C. (2012) · OncoImmunology · doi:10.4161/onci.21716 · Cited by 389 · see citing works

Indoleamine 2,3‐dioxygenase contributes to tumor cell evasion of T cell‐mediated rejection

Friberg, M., Jennings, R., Alsarraj, M., Dessureault, S., Cantor, A. B., Extermann, M., Mellor, A. L., Munn, D. H., & Antonia, S. J. (2002) · International Journal of Cancer · doi:10.1002/ijc.10645 · Cited by 366 · see citing works

Creating immune privilege: active local suppression that benefits friends, but protects foes

Mellor, A. L., & Munn, D. H. (2007) · Nature reviews. Immunology · doi:10.1038/nri2233 · Cited by 327 · see citing works

In situ immune response after neoadjuvant chemotherapy for breast cancer predicts survival

Ladoire, S., Mignot, G., Dabakuyo‐Yonli, T. S., Arnould, L., Apétoh, L., Rébé, C., Coudert, B. P., Martin, F., Bizollon, M.-H., Vanoli, A., et al. (2011) · The Journal of Pathology · doi:10.1002/path.2866 · Cited by 226 · see citing works

Phase III Trial Comparing Three Doses of Docetaxel for Second-Line Treatment of Advanced Breast Cancer

Harvey, V. J., Mouridsen, H. T., Семиглазов, В. Ф., Jakobsen, E. H., Voznyi, E., Robinson, B. A., Groult, V., Murawsky, M., & Cold, S. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.0294 · Cited by 155 · see citing works

Blocking IDO activity to enhance anti-tumor immunity

Munn, D. H. (2012) · Frontiers in Bioscience-Elite · doi:10.2741/e414 · Cited by 136 · see citing works

Blocking IDO activity to enhance anti-tumor immunity

David, H. M. (2011) · Frontiers in Bioscience-Elite · doi:10.2741/414 · Cited by 114 · see citing works

T-bet expression in intratumoral lymphoid structures after neoadjuvant trastuzumab plus docetaxel for HER2-overexpressing breast carcinoma predicts survival

Ladoire, S., Arnould, L., Mignot, G., Apétoh, L., Rébé, C., Martin, F., Fumoleau, P., Coudert, B. P., & Ghiringhelli, F. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.261 · Cited by 66 · see citing works

Enhancement of tumor radioresponse by docetaxel: Involvement of immune system

Mason, K. A., Staab, A., Hunter, N. R., McBride, W. H., Petersen, S. H., Terry, N. H. A., & Milas, L. (2001) · International Journal of Oncology · doi:10.3892/ijo.18.3.599 · Cited by 55 · see citing works

The interplay between the immune system and chemotherapy: emerging methods for optimizing therapy

Ghiringhelli, F., & Apétoh, L. (2013) · Expert Review of Clinical Immunology · doi:10.1586/1744666x.2014.865520 · Cited by 55 · see citing works

Docetaxel: Standard Recommended Dose of 100 mg/m2 Is Effective But Not Feasible for Some Metastatic Breast Cancer Patients Heavily Pretreated With Chemotherapy—A Phase II Single-Center Study

Salminen, E. K., Bergman, M., Huhtala, S., & Ekholm, E. M. K. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1127 · Cited by 51 · see citing works

Checkpoint Modulation in Melanoma: An Update on Ipilimumab and Future Directions

Page, D. B., Postow, M. A., Callahan, M. K., & Wolchok, J. D. (2013) · Current Oncology Reports · doi:10.1007/s11912-013-0337-1 · Cited by 21 · see citing works

A phase I study of 1-methyl-D-tryptophan in patients with advanced malignancies.

Soliman, H. H., Neuger, A. M., Noyes, D. R., Vahanian, N. N., Link, C. J., Munn, D. H., STREICHER, H. Z., Sullivan, D. M., & Antonia, S. J. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.30.15_suppl.2501 · Cited by 17 · see citing works

Phase II Multicenter Study of Docetaxel and Bevacizumab With or Without Trastuzumab as First-Line Treatment for Patients With Metastatic Breast Cancer

Schwartzberg, L. S., Badarinath, S., Keaton, M. R., & Childs, B. H. (2014) · Clinical Breast Cancer · doi:10.1016/j.clbc.2013.12.003 · Cited by 12 · see citing works

Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy

Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229 · see citing works

Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden

Chalmers, Z. R., Connelly, C. F., Fabrizio, D., Gay, L., Ali, S. M., Ennis, R., Schrock, A., Campbell, B., Shlien, A., Chmielecki, J., et al. (2017) · Genome Medicine · doi:10.1186/s13073-017-0424-2 · Cited by 3,519 · see citing works

Tryptophan metabolism as a common therapeutic target in cancer, neurodegeneration and beyond

Platten, M., Nollen, E. A. A., Röhrig, U. F., Fallarino, F., & Opitz, C. A. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0016-5 · Cited by 1,586 · see citing works

Combination cancer immunotherapy and new immunomodulatory targets

Mahoney, K. M., Rennert, P. D., & Freeman, G. J. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4591 · Cited by 1,294 · see citing works

Coinhibitory Pathways in Immunotherapy for Cancer

Baumeister, S. H. C., Freeman, G. J., Dranoff, G., & Sharpe, A. H. (2016) · Annual Review of Immunology · doi:10.1146/annurev-immunol-032414-112049 · Cited by 912 · see citing works

Breast Cancer Immunotherapy: Facts and Hopes

Emens, L. A. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-3001 · Cited by 876 · see citing works

Evolving synergistic combinations of targeted immunotherapies to combat cancer

Melero, I., Berman, D. M., Aznar, M. A., Korman, A. J., Perez‐Gracia, J. L., & Haanen, J. B. A. G. (2015) · Nature reviews. Cancer · doi:10.1038/nrc3973 · Cited by 633 · see citing works

Discovery of IDO1 Inhibitors: From Bench to Bedside

Prendergast, G. C., Malachowski, W. P., DuHadaway, J. B., & Muller, A. J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2285 · Cited by 563 · see citing works

Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets

Shi, Y.-F., Du, L., Lin, L.-Y., & Wang, Y. (2016) · Nature reviews. Drug discovery · doi:10.1038/nrd.2016.193 · Cited by 409 · see citing works

Targeting the IDO1 pathway in cancer: from bench to bedside

Liu, M., Wang, X., Wang, L., Ma, X., Gong, Z., Zhang, S., & Li, Y. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0644-y · Cited by 449 · see citing works

IDO1 in cancer: a Gemini of immune checkpoints

Zhai, L., Ladomersky, E., Lenzen, A. C., Nguyen, B., Patel, R., Lauing, K. L., Wu, M., & Wainwright, D. A. (2018) · Cellular and Molecular Immunology · doi:10.1038/cmi.2017.143 · Cited by 441 · see citing works

Nano-enabled pancreas cancer immunotherapy using immunogenic cell death and reversing immunosuppression

Lu, J., Liu, X., Liao, Y., Salazar, F. B., Sun, B., Jiang, W., Chang, C. H., Jiang, J., Wang, X., Wu, A. M., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01651-9 · Cited by 441 · see citing works

Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan–Kynurenine–Aryl Hydrocarbon Axis

Labadie, B. W., Bao, R., & Luke, J. J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2882 · Cited by 413 · see citing works

Molecular Pathways: Targeting IDO1 and Other Tryptophan Dioxygenases for Cancer Immunotherapy

Zhai, L., Spranger, S., Binder, D. C., Gritsina, G., Lauing, K. L., Giles, F. J., & Wainwright, D. A. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0420 · Cited by 325 · see citing works

Epigenetic therapy for ovarian cancer: promise and progress

Moufarrij, S., Dandapani, M., Arthofer, E., Gomez, S., Srivastava, A., Lopez-Acevedo, M., Villagra, A., & Chiappinelli, K. B. (2019) · Clinical Epigenetics · doi:10.1186/s13148-018-0602-0 · Cited by 318 · see citing works

Emerging Opportunities and Challenges in Cancer Immunotherapy

Whiteside, T. L., Demaria, S., Rodriguez-Ruiz, M. E., Zarour, H. M., & Melero, I. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0049 · Cited by 318 · see citing works

Tumor indoleamine 2,3-dioxygenase (IDO) inhibits CD19-CAR T cells and is downregulated by lymphodepleting drugs

Ninomiya, S., Narala, N., Huye, L. E., Yagyu, S., Savoldo, B., Dotti, G., Heslop, H. E., Brenner, M. K., Rooney, C. M., & Ramos, C. A. (2015) · Blood · doi:10.1182/blood-2015-01-621474 · Cited by 317 · see citing works

Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy

Fujiwara, Y., Kato, S., Nesline, M., Conroy, J. M., DePietro, P., Pabla, S., & Kurzrock, R. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102461 · Cited by 307 · see citing works

The therapeutic potential of targeting tryptophan catabolism in cancer

Opitz, C. A., Somarribas Patterson, L. F., Mohapatra, S. R., Dewi, D. L., Sadik, A., Platten, M., & Trump, S. (2020) · British Journal of Cancer · doi:10.1038/s41416-019-0664-6 · Cited by 300 · see citing works

Immune control by amino acid catabolism during tumorigenesis and therapy

Lemos, H. D. P., Huang, L., Prendergast, G. C., & Mellor, A. L. (2019) · Nature reviews. Cancer · doi:10.1038/s41568-019-0106-z · Cited by 275 · see citing works

Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer

Prendergast, G. C., Malachowski, W. P., Mondal, A., Scherle, P., & Muller, A. J. (2017) · International review of cytology · doi:10.1016/bs.ircmb.2017.07.004 · Cited by 274 · see citing works

The rationale of indoleamine 2,3-dioxygenase inhibition for cancer therapy

Brochez, L., Chevolet, I., & Krüse, V. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.011 · Cited by 268 · see citing works

Second- and third-generation drugs for immuno-oncology treatment—The more the better?

Dempke, W. C. M., Fenchel, K., Uciechowski, P., & Dale, S. P. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.001 · Cited by 260 · see citing works

T Regulatory Cells and Priming the Suppressive Tumor Microenvironment

Paluskievicz, C., Cao, X., Abdi, R., Zheng, P., Liu, Y., & Bromberg, J. S. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02453 · Cited by 252 · see citing works

Role of indoleamine 2,3-dioxygenase in health and disease

Yeung, A. W. S., Terentis, A. C., King, N. J. C., & Thomas, S. R. (2015) · Clinical Science · doi:10.1042/cs20140392 · Cited by 235 · see citing works

Tumor-intrinsic signaling pathways: key roles in the regulation of the immunosuppressive tumor microenvironment

Yang, L., Li, A., Lei, Q., & Zhang, Y. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0804-8 · Cited by 215 · see citing works

USP14 promotes tryptophan metabolism and immune suppression by stabilizing IDO1 in colorectal cancer

Shi, D., Wu, X., Jian, Y., Wang, J., Huang, C., Mo, S., Li, Y., Li, F., Zhang, C., Zhang, D., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33285-x · Cited by 214 · see citing works

Human Tumor-Infiltrating Myeloid Cells: Phenotypic and Functional Diversity

Elliott, L., Doherty, G. A., Sheahan, K. D., & Ryan, E. J. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00086 · Cited by 208 · see citing works

Updates on immunotherapy for colorectal cancer

Kalyan, A., Kircher, S. M., Shah, H. A., Mulcahy, M. F., & Benson, A. B. (2018) · Journal of Gastrointestinal Oncology · doi:10.21037/jgo.2018.01.17 · Cited by 178 · see citing works

Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer

Lanser, L., Kink, P., Egger, E. M., Willenbacher, W., Fuchs, D., Weiß, G., & Kurz, K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00249 · Cited by 172 · see citing works

The Kynurenine Pathway is a Double-Edged Sword in Immune-Privileged Sites and in Cancer: Implications for Immunotherapy

Routy, J., Routy, B., Graziani, G. M., & Mehraj, V. (2016) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s38355 · Cited by 171 · see citing works

IDO1: An important immunotherapy target in cancer treatment

Li, F., Zhang, R., Li, S., & Liu, J. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.03.024 · Cited by 160 · see citing works

Dysfunctional T cell metabolism in the tumor microenvironment

Beckermann, K. E., Dudzinski, S. O., & Rathmell, J. C. (2017) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2017.04.003 · Cited by 159 · see citing works

miR-153 suppresses IDO1 expression and enhances CAR T cell immunotherapy

Huang, Q., Xia, J., Wang, L., Wang, X., Ma, X., Deng, Q., Lu, Y., Kumar, M., Zhou, Z., Li, L., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0600-x · Cited by 137 · see citing works

Indoleamine 2,3-dioxygenase (Ido) inhibitors and their nanomedicines for cancer immunotherapy

Guo, Y., Liu, Y., Wu, W., Ling, D., Zhang, Q., Peng, Z. M., & Hu, X. (2021) · Biomaterials · doi:10.1016/j.biomaterials.2021.121018 · Cited by 132 · see citing works

Limitations and Off-Target Effects of Tryptophan-Related IDO Inhibitors in Cancer Treatment

Günther, J., Däbritz, J., & Wirthgen, E. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01801 · Cited by 133 · see citing works

Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer

Fox, E. E., Oliver, T., Rowe, M. M., Thomas, S., Zakharia, Y., Gilman, P. B., Muller, A. J., & Prendergast, G. C. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00370 · Cited by 125 · see citing works

Tryptophan Catabolism in Chronic Viral Infections: Handling Uninvited Guests

Mehraj, V., & Routy, J. (2015) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s26862 · Cited by 122 · see citing works

Opportunities for Small Molecules in Cancer Immunotherapy

van der Zanden, S. Y., Luimstra, J. J., Neefjes, J., Borst, J., & Ovaa, H. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.04.004 · Cited by 119 · see citing works

Modulation of Cancer-Specific Immune Responses by Amino Acid Degrading Enzymes

Timosenko, E., Hadjinicolaou, A. V., & Cerundolo, V. (2016) · Immunotherapy · doi:10.2217/imt-2016-0118 · Cited by 100 · see citing works

Recent advances in small molecule based cancer immunotherapy

Cheng, B., Yuan, W., Su, J., Liu, Y., & Chen, J. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.08.028 · Cited by 100 · see citing works

Targeting indoleamine-2,3-dioxygenase in cancer: Scientific rationale and clinical evidence

Ricciuti, B., Leonardi, G. C., Puccetti, P., Fallarino, F., Bianconi, V., Sahebkar, A., Baglivo, S., Chiari, R., & Pirro, M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.12.004 · Cited by 96 · see citing works

Immunogenic-cell-killing and immunosuppression-inhibiting nanomedicine

Wang, Y., Gao, D., Liu, Y., Guo, X., Chen, S., Zeng, L., Ma, J., Zhang, X., Tian, Z., & Yang, Z. (2020) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.11.016 · Cited by 93 · see citing works

IDO expression in breast cancer: an assessment of 281 primary and metastatic cases with comparison to PD-L1

Dill, E. A., Dillon, P. M., Bullock, T. N. J., & Mills, A. M. (2018) · Modern Pathology · doi:10.1038/s41379-018-0061-3 · Cited by 92 · see citing works

IDO1 Expression Is Associated With Immune Tolerance and Poor Prognosis in Patients With Surgically Resected Esophageal Cancer

Kiyozumi, Y., Baba, Y., Okadome, K., Yagi, T., Ishimoto, T., Iwatsuki, M., Miyamoto, Y., Yoshida, N., Watanabe, M., Komohara, Y., et al. (2018) · Annals of Surgery · doi:10.1097/sla.0000000000002754 · Cited by 88 · see citing works

Tryptophan Catabolism and Cancer Immunotherapy Targeting IDO Mediated Immune Suppression

Amobi, A. E., Qian, F., Lugade, A. A., & Odunsi, K. O. (2017) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-67577-0_9 · Cited by 88 · see citing works

Recent advances in clinical trials targeting the kynurenine pathway

Pires, A. S., Sundaram, G., Heng, B., Krishnamurthy, S., Brew, B. J., & Guillemin, G. J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.108055 · Cited by 84 · see citing works

Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model

Hanihara, M., Kawataki, T., Oh‐oka, K., Mitsuka, K., Nakao, A., & Kinouchi, H. (2015) · Journal of neurosurgery · doi:10.3171/2015.5.jns141901 · Cited by 84 · see citing works

Fueling the engine and releasing the break: combinational therapy of cancer vaccines and immune checkpoint inhibitors.

Kleponis, J., Skelton, R. A., & Zheng, L. (2015) · Europe PMC (PubMed Central) · doi:10.7497/j.issn.2095-3941.2015.0046 · Cited by 91 · see citing works

Role of immunotherapy in bladder cancer: past, present and future

Butt, S.-U.-R., & Malik, L. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-018-3518-7 · Cited by 74 · see citing works

Indoleamine 2,3-Dioxygenase (IDO) Inhibition as a Strategy to Augment Cancer Immunotherapy

Yentz, S. E., & Smith, D. C. (2018) · BioDrugs · doi:10.1007/s40259-018-0291-4 · Cited by 70 · see citing works

Emerging therapeutic targets in metastatic progression: A focus on breast cancer

Li, Z., & Kang, Y. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.03.003 · Cited by 71 · see citing works

Role of tryptophan metabolism in cancers and therapeutic implications

Liu, X., & Zhai, X. (2021) · Biochimie · doi:10.1016/j.biochi.2021.01.005 · Cited by 70 · see citing works

Major Developments in the Design of Inhibitors along the Kynurenine Pathway

Jacobs, K. R., Castellano‐González, G., Guillemin, G. J., & Lovejoy, D. B. (2017) · Current Medicinal Chemistry · doi:10.2174/0929867324666170502123114 · Cited by 63 · see citing works

Small-Molecule Targets in Immuno-Oncology

Dhanak, D., Edwards, J. P., Nguyen, A., & Tummino, P. J. (2017) · Cell chemical biology · doi:10.1016/j.chembiol.2017.08.019 · Cited by 64 · see citing works

Context Drives Diversification of Monocytes and Neutrophils in Orchestrating the Tumor Microenvironment

Jeong, J., Suh, Y., & Jung, K. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01817 · Cited by 60 · see citing works

Reversal of schizophrenia-like symptoms and immune alterations in mice by immunomodulatory drugs

Araújo, T. D. S., Filho, A. J. M. C., Monte, A. S., Queiroz, A. I. D. G., Cordeiro, R. C., Machado, M. D. J. S., Lima, R. D. F., de Lucena, D. F., Maes, M. H. J., & Macêdo, D. S. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.09.017 · Cited by 52 · see citing works

Effect of Taxane Chemotherapy With or Without Indoximod in Metastatic Breast Cancer

Mariotti, V., Han, H. S., Ismail-Khan, R. R., Tang, S., Dillon, P. M., Montero, A. J., Poklepovic, A. S., Melin, S. A., Ibrahim, N. K., Kennedy, E. P., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.5572 · Cited by 52 · see citing works

Trial Watch—Small molecules targeting the immunological tumor microenvironment for cancer therapy

Buqué, A., Bloy, N., Aranda, F., Cremer, I., Eggermont, A. M. M., Fridman, W. H., Fucikova, J. P., Galon, J., Špíšek, R., Tartour, É., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1149674 · Cited by 50 · see citing works

Immunosuppressive enzymes in the tumor microenvironment

Molinier‐Frenkel, V., & Castellano, F. (2017) · FEBS Letters · doi:10.1002/1873-3468.12784 · Cited by 50 · see citing works

PD ‐L1 and IDO expression in cervical and vulvar invasive and intraepithelial squamous neoplasias: implications for combination immunotherapy

Chinn, Z., Stoler, M. H., & Mills, A. M. (2018) · Histopathology · doi:10.1111/his.13723 · Cited by 50 · see citing works

Targeting immune checkpoints in malignant glioma

Zhang, X., Zhu, S., Li, T., Liu, Y., Chen, W., & Chen, J. (2016) · Oncotarget · doi:10.18632/oncotarget.12702 · Cited by 49 · see citing works

Objective measurement and clinical significance of IDO1 protein in hormone receptor-positive breast cancer

Carvajal‐Hausdorf, D., Mani, N. L., Velcheti, V., Schalper, K. A., & Rimm, D. L. (2017) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0285-7 · Cited by 51 · see citing works

Design, synthesis and biological evaluation of indole-2-carboxylic acid derivatives as IDO1/TDO dual inhibitors

Cui, G., Lai, F., Wang, X., Chen, X., & Xu, B. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111985 · Cited by 48 · see citing works

Targeting Indoleamine Dioxygenase and Tryptophan Dioxygenase in Cancer Immunotherapy: Clinical Progress and Challenges

Peng, X., Zhao, Z., Liu, L., Bai, L., Tong, R., Yang, H., & Zhong, L. (2022) · Drug Design Development and Therapy · doi:10.2147/dddt.s373780 · Cited by 47 · see citing works

Localized Multi‐Component Delivery Platform Generates Local and Systemic Anti‐Tumor Immunity

Acharya, A. P., Sinha, M. K., Ratay, M. L., Ding, X., Balmert, S. C., Workman, C. J., Wang, Y., Vignali, D. A. A., & Little, S. R. (2016) · Advanced Functional Materials · doi:10.1002/adfm.201604366 · Cited by 46 · see citing works

The ups, downs and new trends of IDO1 inhibitors

Chen, S., Tan, J., & Zhang, A. (2021) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2021.104815 · Cited by 47 · see citing works

Mesenchymal Stromal Cells: What Is the Mechanism in Acute Graft-Versus-Host Disease?

Dunavin, N., Dias, A., Li, M., & McGuirk, J. P. (2017) · Biomedicines · doi:10.3390/biomedicines5030039 · Cited by 46 · see citing works

Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential

Wurz, G. T., Kao, C.-J., & DeGregorio, M. W. (2015) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834015615514 · Cited by 45 · see citing works

Immunotherapy in ovarian cancer

Krishnan, V., Berek, J. S., & Dorigo, O. (2016) · Current Problems in Cancer · doi:10.1016/j.currproblcancer.2016.11.003 · Cited by 48 · see citing works

Therapeutic antibody targeting of indoleamine-2,3-dioxygenase (IDO2) inhibits autoimmune arthritis

Merlo, L. M. F., Grabler, S., DuHadaway, J. B., Pigott, E., Manley, K., Prendergast, G. C., Laury‐Kleintop, L. D., & Mandik‐Nayak, L. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.01.016 · Cited by 45 · see citing works

The kynurenine pathway in HIV, frailty and inflammaging

Sultana, S., Elengickal, A. J., Bensreti, H., de Chantemèle, E. J. B., McGee‐Lawrence, M. E., & Hamrick, M. W. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1244622 · Cited by 39 · see citing works

Indoleamine 2,3-Dioxygenase Expression Pattern in the Tumor Microenvironment Predicts Clinical Outcome in Early Stage Cervical Cancer

Heeren, A. M., van Dijk, I., Berry, D. R. A. I., Khelil, M., Ferns, D. M., Kole, J., Musters, R. J. P., Thijssen, V. L., Mom, C. H., Kenter, G. G., et al. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01598 · Cited by 39 · see citing works

Discovery of indoximod prodrugs and characterization of clinical candidate NLG802

Kumar, S., Jaipuri, F. A., Waldo, J. P., Potturi, H., Marcinowicz, A., Adams, J., Allen, C. V., Zhuang, H., Vahanian, N. N., Link, C., et al. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112373 · Cited by 39 · see citing works

The kynurenine pathway presents multi-faceted metabolic vulnerabilities in cancer

Léon-Letelier, R. A., Dou, R., Vykoukal, J. V., Sater, A. H. A., Ostrin, E. J., Hanash, S., & Fahrmann, J. F. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1256769 · Cited by 39 · see citing works

Immunotherapy for breast cancer: past, present, and future

Spellman, A., & Tang, S.-C. (2016) · Cancer and Metastasis Reviews · doi:10.1007/s10555-016-9654-9 · Cited by 38 · see citing works

Exploring optimal sequencing of radiation and immunotherapy combinations

Gunderson, A. J., & Young, K. H. (2018) · Advances in Radiation Oncology · doi:10.1016/j.adro.2018.07.005 · Cited by 38 · see citing works

Tryptophan catabolites along the indoleamine 2,3-dioxygenase pathway as a biological link between depression and cancer

Barreto, F. S., Filho, A. J. M. C., Araújo, M. C., de Moraes, M. O., de Moraes, M. E. A., Maes, M. H. J., de Lucena, D. F., & Macêdo, D. S. (2018) · Behavioural Pharmacology · doi:10.1097/fbp.0000000000000384 · Cited by 36 · see citing works

New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1

Villanueva, N., & Bazhenova, L. A. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753466618794133 · Cited by 37 · see citing works

Indoximod opposes the immunosuppressive effects mediated by IDO and TDO via modulation of AhR function and activation of mTORC1

Brincks, E. L., Adams, J., Wang, L., Turner, B. A., Marcinowicz, A., Ke, J., Essmann, M., Mautino, L. M., Allen, C. V., Kumar, S., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27646 · Cited by 37 · see citing works

Recent advances in the discovery of indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors

Wang, X., Sun, S.-Y., Dong, Q.-Q., Wu, X.-X., Tang, W., & Xing, Y.-Q. (2019) · MedChemComm · doi:10.1039/c9md00208a · Cited by 35 · see citing works

Targeting tumor tolerance: A new hope for pancreatic cancer therapy?

Delitto, D., Wallet, S. M., & Hughes, S. J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.06.008 · Cited by 36 · see citing works

Role of indoleamine 2,3-dioxygenase in pathology of the gastrointestinal tract

Acović, A., Gazdic, M., Jovicic, N. U., Harrell, C. R., Fellabaum, C., Arsenijević, N., & Volarević, V. (2018) · Therapeutic Advances in Gastroenterology · doi:10.1177/1756284818815334 · Cited by 35 · see citing works

Harnessing the immune system in the battle against breast cancer

Nakasone, E. S., Hurvitz, S. A., & McCann, K. E. (2018) · Drugs in Context · doi:10.7573/dic.212520 · Cited by 33 · see citing works

Small molecule drugs with immunomodulatory effects in cancer

Murphy, A. G., & Zheng, L. (2015) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2015.1057363 · Cited by 32 · see citing works

IDO and TDO inhibitors in cancer immunotherapy: mechanisms, clinical development, and future directions

Al‐Zoubi, R. M., Elaarag, M., Al-Qudimat, A. R., Al-Hurani, E. A., Fares, Z. E., Farhan, A., Al-Zoubi, S. R., Khan, A., Agouni, A., Shkoor, M., et al. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1632446 · Cited by 30 · see citing works

Abnormal Tryptophan Metabolism in HIV and Mycobacterium tuberculosis Infection

Wang, X., Mehra, S., Kaushal, D., Veazey, R. S., & Xu, H. (2021) · Frontiers in Microbiology · doi:10.3389/fmicb.2021.666227 · Cited by 28 · see citing works

Kynurenines as a Novel Target for the Treatment of Malignancies

Mor, A., Tankiewicz‐Kwedlo, A., & Pawlak, D. (2021) · Pharmaceuticals · doi:10.3390/ph14070606 · Cited by 30 · see citing works

Heme-containing enzymes and inhibitors for tryptophan metabolism

Yan, D., Lin, Y., & Tan, X. (2017) · Metallomics · doi:10.1039/c7mt00105c · Cited by 29 · see citing works

Imaging tryptophan uptake with positron emission tomography in glioblastoma patients treated with indoximod

Lukas, R. V., Juhász, C., Wainwright, D. A., James, C. D., Kennedy, E. P., Stupp, R., & Lesniak, M. S. (2018) · Journal of Neuro-Oncology · doi:10.1007/s11060-018-03013-x · Cited by 29 · see citing works

Molecular Mechanisms and Potential Therapeutic Reversal of Pancreatic Cancer-Induced Immune Evasion

Gan, L.-L., Hii, L., Wong, S. F., Leong, C., & Mai, C. (2020) · Cancers · doi:10.3390/cancers12071872 · Cited by 28 · see citing works

T Lymphocyte–Based Cancer Immunotherapeutics

Borrie, A. E., & Vareki, S. M. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.05.010 · Cited by 27 · see citing works

The Immunomodulatory Enzyme IDO2 Mediates Autoimmune Arthritis through a Nonenzymatic Mechanism

Merlo, L. M. F., Peng, W., DuHadaway, J. B., Montgomery, J. D., Prendergast, G. C., Muller, A. J., & Mandik‐Nayak, L. (2021) · The Journal of Immunology · doi:10.4049/jimmunol.2100705 · Cited by 26 · see citing works

Signaling Circuits and Regulation of Immune Suppression by Ovarian Tumor-Associated Macrophages

Cannon, M. J., Ghosh, D., & Gujja, S. (2015) · Vaccines · doi:10.3390/vaccines3020448 · Cited by 26 · see citing works

Folate Receptor-Mediated Delivery of 1-MDT-Loaded Mesoporous Silica Magnetic Nanoparticles to Target Breast Cancer Cells

Hashemzadeh, N., Dolatkhah, M., Aghanejad, A., Barzegar-Jalali, M., Omidi, Y., Adibkia, K., & Barar, J. (2021) · Nanomedicine · doi:10.2217/nnm-2021-0176 · Cited by 25 · see citing works

Molecular Markers of Regulatory T Cells in Cancer Immunotherapy with Special Focus on Acute Myeloid Leukemia (AML) - A Systematic Review

Kaboli, P. J., Zhang, L., Xiang, S., Shen, J., Li, M., Zhao, Y., Wu, X., Zhao, Q., Zhang, H., Lin, L., et al. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666191004164041 · Cited by 24 · see citing works

A combination of nanosystems for the delivery of cancer chemoimmunotherapeutic combinations: 1-Methyltryptophan nanocrystals and paclitaxel nanoparticles

Calleja, P., Irache, J. M., Zandueta, C., Martínez-Ohárriz, M. C., & Espuelas, S. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.09.004 · Cited by 23 · see citing works

Targeting Leukemia Stem Cells in the Bone Marrow Niche

Tasian, S. K., Bornhäuser, M., & Rutella, S. (2018) · Biomedicines · doi:10.3390/biomedicines6010022 · Cited by 23 · see citing works

Nanodelivery Optimization of IDO1 Inhibitors in Tumor Immunotherapy: Challenges and Strategies

Jiang, K., Wang, Q., Chen, X., Wang, X., Gu, X., Feng, S., Wu, J., Shang, H., Ba, X., Zhang, Y., et al. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s458086 · Cited by 21 · see citing works

A phase I study of indoximod in combination with docetaxel in metastatic solid tumors.

Jackson, E., Dees, E. C., Kauh, J. S. W., Harvey, R. D., Neuger, A. M., Lush, R. M., Antonia, S. J., Minton, S. E., Ismail-Khan, R. R., Han, H. S., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3026 · Cited by 22 · see citing works

A Phase 2 Study of Docetaxel in Combination with Indoximod for Metastatic Breast Cancer

Kennedy, E. P., Soliman, H. H., Ismail-Khan, R. R., Han, H. S., Rossi, G. R., Vahanian, N. N., Link, C., Sullivan, D. M., & Antonia, S. J. (2014) · Annals of Oncology · doi:10.1093/annonc/mdu467.15 · Cited by 2 · see citing works

Abstract P2-11-09: A phase 2 randomized trial of the IDO pathway inhibitor indoximod in combination with taxane based chemotherapy for metastatic breast cancer: Preliminary data

Tang, S.-C., Montero, A., Munn, D. H., Link, C., Vahanian, N. N., Kennedy, E. P., & Soliman, H. (2016) · Cancer Research · doi:10.1158/1538-7445.sabcs15-p2-11-09 · Cited by 6 · see citing works

A phase 2 study of docetaxel in combination with indoximod in metastatic breast cancer.

Soliman, H. H., Minton, S. E., Ismail-Khan, R. R., Han, H. S., Vahanian, N. N., Ramsey, W. J., Kennedy, E. P., Link, C. J., Sullivan, D. M., & Antonia, S. J. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.tps3124 · Cited by 12 · see citing works

A phase I study of indoximod in patients with advanced malignancies

Soliman, H. H., Minton, S. E., Han, H. S., Ismail-Khan, R. R., Neuger, A. M., Khambati, F. A., Noyes, D. R., Lush, R. M., Chiappori, A., Roberts, J. D., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8216 · Cited by 145 · see citing works